Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

Ocean Biomedical (OCEA) announced that the China National Intellectual Property Administration has granted a notice of grant on patent right ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

Bispecific antibodies (bsAbs) represent a significant advancement in biologic therapeutics, offering enhanced therapeutic efficacy through dual antigen tar | Ebooks ...

Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn’s and Colitis Organization in Inflammatory Bowel ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Compass ...

Context Therapeutics Inc.’s CNTX share price has dipped by 11.07%, which has investors questioning if this is right time to buy.

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, has entered into a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation (MTPC). Under this ...